300 related articles for article (PubMed ID: 18337218)
1. Liposomal nanomedicines: an emerging field.
Fenske DB; Chonn A; Cullis PR
Toxicol Pathol; 2008 Jan; 36(1):21-9. PubMed ID: 18337218
[TBL] [Abstract][Full Text] [Related]
2. Liposomal nanomedicines.
Fenske DB; Cullis PR
Expert Opin Drug Deliv; 2008 Jan; 5(1):25-44. PubMed ID: 18095927
[TBL] [Abstract][Full Text] [Related]
3. Entrapment of small molecules and nucleic acid-based drugs in liposomes.
Fenske DB; Cullis PR
Methods Enzymol; 2005; 391():7-40. PubMed ID: 15721372
[TBL] [Abstract][Full Text] [Related]
4. Targeting liposomal nanomedicine to cancer therapy.
Zhong J; Dai LC
Technol Cancer Res Treat; 2012 Oct; 11(5):475-81. PubMed ID: 22475065
[TBL] [Abstract][Full Text] [Related]
5. Liposomal drug delivery systems: from concept to clinical applications.
Allen TM; Cullis PR
Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225
[TBL] [Abstract][Full Text] [Related]
6. Anticancer drug delivery with nanoparticles.
Conti M; Tazzari V; Baccini C; Pertici G; Serino LP; De Giorgi U
In Vivo; 2006; 20(6A):697-701. PubMed ID: 17203748
[TBL] [Abstract][Full Text] [Related]
7. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
Constantinides PP; Chaubal MV; Shorr R
Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
[TBL] [Abstract][Full Text] [Related]
8. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
Bharali DJ; Mousa SA
Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional nanoparticles--properties and prospects for their use in human medicine.
Sanvicens N; Marco MP
Trends Biotechnol; 2008 Aug; 26(8):425-33. PubMed ID: 18514941
[TBL] [Abstract][Full Text] [Related]
10. Liposomal nanomedicines in the treatment of prostate cancer.
Kroon J; Metselaar JM; Storm G; van der Pluijm G
Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting toxicity and efficacy of polymeric nanomedicines.
Igarashi E
Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle formulations in pulmonary drug delivery.
Bailey MM; Berkland CJ
Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
[TBL] [Abstract][Full Text] [Related]
13. Oral delivery of siRNA and antisense oligonucleotides.
Akhtar S
J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
[TBL] [Abstract][Full Text] [Related]
14. Theranostic nanomedicine.
Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
[TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
16. SiRNA delivery: challenges and role of carrier systems.
Shegokar R; Al Shaal L; Mishra PR
Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
[TBL] [Abstract][Full Text] [Related]
17. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
Malam Y; Loizidou M; Seifalian AM
Trends Pharmacol Sci; 2009 Nov; 30(11):592-9. PubMed ID: 19837467
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
19. Liposomes in ultrasonic drug and gene delivery.
Huang SL
Adv Drug Deliv Rev; 2008 Jun; 60(10):1167-76. PubMed ID: 18479776
[TBL] [Abstract][Full Text] [Related]
20. Lipid nanocapsules: a new platform for nanomedicine.
Huynh NT; Passirani C; Saulnier P; Benoit JP
Int J Pharm; 2009 Sep; 379(2):201-9. PubMed ID: 19409468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
